HC010
Phase 2Small molecule
HC010 is one of 145 small molecule programs targeting Advanced Solid Tumors. It is currently in Phase 2.
4
Indications
4
Total Trials
4
Active Trials
144
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
311 competitors in Advanced Solid Tumors
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Alimta
SShawn Eagle
Phase 2
Recentin
NNational Cancer Institute (NCI)
Phase 2
BNT327
BioNTechPhase 2
Standard Chemotherapy
RochePhase 2
IL-2
FFate Therapeutics
Phase 2
Ivarmacitinib
FFudan University
Phase 2
HC010
HHC Biopharma Inc.
Phase 2
Test Product HY07121
SSichuan Huiyu Pharmaceutical Co., Ltd
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lung Cancer1 trial
Advanced Solid Tumors1 trial
Patients With Advanced Solid Tumors1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HC010. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHC Biopharma Inc.